Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2022 - 2025)

Atara Biotherapeutics' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $49000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 95.55% year-over-year to $49000.0; the TTM value through Dec 2025 reached $2.1 million, down 58.11%, while the annual FY2025 figure was $2.1 million, 58.11% down from the prior year.
  • Depreciation & Amortization (CF) reached $49000.0 in Q4 2025 per ATRA's latest filing, up from $36000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.8 million in Q1 2025 to a low of $36000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 4 years is $1.1 million, with a median of $1.2 million recorded in 2023.
  • The largest YoY upside for Depreciation & Amortization (CF) was 29.04% in 2025 against a maximum downside of 97.07% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $1.3 million in 2022, then dropped by 3.98% to $1.2 million in 2023, then fell by 8.71% to $1.1 million in 2024, then crashed by 95.55% to $49000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Depreciation & Amortization (CF) are $49000.0 (Q4 2025), $36000.0 (Q3 2025), and $236000.0 (Q2 2025).